27573470|t|Angiopoietin-like protein 4 improves glucose tolerance and insulin resistance but induces liver steatosis in high-fat-diet mice
27573470|a|Angiopoietin-like protein 4 (Angptl4) is a secreted protein predominantly expressed in liver and adipose tissues, and has been identified as an adipokine. Angptl4 is the target gene of peroxisome proliferator‑activated receptors, which are widely used as lipid‑lowering and anti‑diabetic drugs, and previous studies have demonstrated that Angptl4 is able to directly stimulate adipocyte lipolysis. The current study focused on how Angptl4 was involved in regulating lipid and glucose metabolism in high‑fat‑diet (HFD) C57 mice. In the present study, mice were divided into three groups, with standard chow mice as a normal control, adenovirus (adv)‑ injected HFD mice as a model control and adv ‑ Angptl4 ‑ injected HFD mice as the Angptl4+ group. Firstly, compared with the normal control group, mice in the model control group gained more body weight with severe liver steatosis and increased serum levels of triglyceride, total cholesterol, free fatty acids, alanine aminotransferase and aspartate aminotransferase. In the Angptl4+ group, Angptl4 reduced the weight growth rate, aggravated hepatic steatosis and further increased all the aforementioned serum indexes. Secondly, compared with the normal control, the model control group had a reduced glucose tolerance and developed insulin resistance. Angptl4 expression and the phosphorylation levels of several insulin signaling pathway‑associated genes, insulin receptor substrate 1, protein kinase B, janus kinase 2, signal transducer and activator of transcription 3 were downregulated in the liver samples. Adv ‑ Angptl4 injection was observed to improve glucose tolerance and insulin resistance. The genes measured were identified to be upregulated close to normal levels. All the results suggested that Angptl4 served an important role in lipid and glucose metabolism in HFD‑induced obese mice, and this may have a great significance for treatment of hyperlipidemia, diabetes, metabolic syndrome and other diseases.
27573470	0	27	Angiopoietin-like protein 4	T103	UMLS:C1438918
27573470	28	36	improves	T033	UMLS:C0184511
27573470	59	77	insulin resistance	T038	UMLS:C0021655
27573470	90	105	liver steatosis	T038	UMLS:C0015695
27573470	109	127	high-fat-diet mice	T204	UMLS:C0026809
27573470	128	155	Angiopoietin-like protein 4	T103	UMLS:C1438918
27573470	157	164	Angptl4	T103	UMLS:C1438918
27573470	171	187	secreted protein	T103	UMLS:C0033684
27573470	202	211	expressed	T038	UMLS:C1171362
27573470	215	220	liver	T017	UMLS:C0736268
27573470	225	240	adipose tissues	T017	UMLS:C0001527
27573470	272	281	adipokine	T103	UMLS:C1955907
27573470	283	290	Angptl4	T017	UMLS:C1423931
27573470	305	309	gene	T017	UMLS:C0017337
27573470	313	356	peroxisome proliferator‑activated receptors	T103	UMLS:C0166418
27573470	383	397	lipid‑lowering	T103	UMLS:C0003367
27573470	402	421	anti‑diabetic drugs	T103	UMLS:C1875327
27573470	436	443	studies	T062	UMLS:C2603343
27573470	467	474	Angptl4	T103	UMLS:C1438918
27573470	505	514	adipocyte	T017	UMLS:C0206131
27573470	515	524	lipolysis	T038	UMLS:C0023796
27573470	538	543	study	T062	UMLS:C2603343
27573470	559	566	Angptl4	T103	UMLS:C1438918
27573470	583	599	regulating lipid	T038	UMLS:C1158445
27573470	604	622	glucose metabolism	T038	UMLS:C2612213
27573470	626	654	high‑fat‑diet (HFD) C57 mice	T204	UMLS:C0025929
27573470	671	676	study	T062	UMLS:C2603343
27573470	678	682	mice	T204	UMLS:C0025929
27573470	729	738	chow mice	T204	UMLS:C0025929
27573470	760	770	adenovirus	T005	UMLS:C0001483
27573470	772	775	adv	T005	UMLS:C0001483
27573470	778	795	injected HFD mice	T204	UMLS:C0025929
27573470	819	822	adv	T005	UMLS:C0001483
27573470	825	832	Angptl4	T017	UMLS:C1423931
27573470	835	852	injected HFD mice	T204	UMLS:C0025929
27573470	925	929	mice	T204	UMLS:C0025929
27573470	993	1008	liver steatosis	T038	UMLS:C0015695
27573470	1023	1051	serum levels of triglyceride	T033	UMLS:C1287372
27573470	1053	1070	total cholesterol	T033	UMLS:C1837784
27573470	1072	1088	free fatty acids	T033	UMLS:C0236060
27573470	1090	1114	alanine aminotransferase	T033	UMLS:C0151905
27573470	1119	1145	aspartate aminotransferase	T033	UMLS:C0151904
27573470	1170	1177	Angptl4	T103	UMLS:C1438918
27573470	1221	1238	hepatic steatosis	T038	UMLS:C0015695
27573470	1284	1289	serum	T031	UMLS:C0229671
27573470	1290	1297	indexes	T170	UMLS:C0600653
27573470	1373	1398	reduced glucose tolerance	T033	UMLS:C0151671
27573470	1413	1431	insulin resistance	T038	UMLS:C0021655
27573470	1433	1440	Angptl4	T103	UMLS:C1438918
27573470	1441	1451	expression	T038	UMLS:C1171362
27573470	1460	1475	phosphorylation	T038	UMLS:C0031715
27573470	1494	1530	insulin signaling pathway‑associated	T038	UMLS:C1512804
27573470	1531	1536	genes	T017	UMLS:C0017337
27573470	1538	1566	insulin receptor substrate 1	T103	UMLS:C1505029
27573470	1568	1584	protein kinase B	T103	UMLS:C1449149
27573470	1586	1600	janus kinase 2	T103	UMLS:C1527619
27573470	1602	1652	signal transducer and activator of transcription 3	T103	UMLS:C1530114
27573470	1658	1671	downregulated	T038	UMLS:C0013081
27573470	1679	1692	liver samples	T017	UMLS:C0586688
27573470	1694	1697	Adv	T005	UMLS:C0001483
27573470	1700	1707	Angptl4	T017	UMLS:C1423931
27573470	1734	1741	improve	T033	UMLS:C0184511
27573470	1764	1782	insulin resistance	T038	UMLS:C0021655
27573470	1788	1793	genes	T017	UMLS:C0017337
27573470	1825	1836	upregulated	T038	UMLS:C0041904
27573470	1892	1899	Angptl4	T103	UMLS:C1438918
27573470	1928	1933	lipid	T038	UMLS:C1158445
27573470	1938	1956	glucose metabolism	T038	UMLS:C2612213
27573470	1960	1982	HFD‑induced obese mice	T204	UMLS:C0025933
27573470	2027	2036	treatment	T058	UMLS:C0087111
27573470	2040	2054	hyperlipidemia	T038	UMLS:C0020473
27573470	2056	2064	diabetes	T038	UMLS:C0011847
27573470	2066	2084	metabolic syndrome	T038	UMLS:C0524620
27573470	2095	2103	diseases	T038	UMLS:C0012634